Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 389

1.

Late autophagy inhibitor chloroquine improves efficacy of the histone deacetylase inhibitor SAHA and temozolomide in gliomas.

Gonçalves RM, Agnes JP, Delgobo M, de Souza PO, Thomé MP, Heimfarth L, Lenz G, Moreira JCF, Zanotto-Filho A.

Biochem Pharmacol. 2019 Mar 13. pii: S0006-2952(19)30101-7. doi: 10.1016/j.bcp.2019.03.015. [Epub ahead of print]

PMID:
30878553
2.

Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL).

Reinartz G, Pyra RP, Lenz G, Liersch R, Stüben G, Micke O, Willborn K, Hess CF, Probst A, Fietkau R, Jany R, Schultze J, Rübe C, Hirt C, Fischbach W, Bentz M, Daum S, Pott C, Tiemann M, Möller P, Neubauer A, Wilhelm M, Willich N, Berdel WE, Eich HT.

Strahlenther Onkol. 2019 Mar 11. doi: 10.1007/s00066-019-01446-5. [Epub ahead of print]

PMID:
30859254
3.

Nuclear morphometric analysis in tissue as an objective tool with potential use to improve melanoma staging.

Nunes TWN, Filippi-Chiela EC, Callegari-Jacques SM, da Silva VD, Sansonowicz T, Lenz G, Roehe AV.

Melanoma Res. 2019 Mar 4. doi: 10.1097/CMR.0000000000000594. [Epub ahead of print]

PMID:
30839356
4.

Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.

Cheson BD, O'Brien S, Ewer MS, Goncalves MD, Farooki A, Lenz G, Yu A, Fisher RI, Zinzani PL, Dreyling M.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):135-141. doi: 10.1016/j.clml.2018.11.021. Epub 2018 Nov 29.

5.

esiCancer: Evolutionary In Silico Cancer Simulator.

Minussi DC, Henz B, Dos Santos Oliveira M, Filippi-Chiela EC, Oliveira MM, Lenz G.

Cancer Res. 2019 Mar 1;79(5):1010-1013. doi: 10.1158/0008-5472.CAN-17-3924. Epub 2018 Dec 18.

PMID:
30563892
6.

Darpp-32 and t-Darpp protein products of PPP1R1B: Old dogs with new tricks.

Avanes A, Lenz G, Momand J.

Biochem Pharmacol. 2019 Feb;160:71-79. doi: 10.1016/j.bcp.2018.12.008. Epub 2018 Dec 12. Review.

PMID:
30552871
7.

Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial.

Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, Schmidt C, Ruebe C, Loeffler M, Pfreundschuh M, Rosenwald A, Glass B, Lenz G, Schmitz N; German high-grade lymphoma Study Group.

Br J Haematol. 2019 Mar;184(5):760-768. doi: 10.1111/bjh.15710. Epub 2018 Dec 5.

PMID:
30520013
8.

Chromatin conformation analysis of primary patient tissue using a low input Hi-C method.

Díaz N, Kruse K, Erdmann T, Staiger AM, Ott G, Lenz G, Vaquerizas JM.

Nat Commun. 2018 Nov 29;9(1):4938. doi: 10.1038/s41467-018-06961-0.

9.

EMT-like process in glioblastomas and reactive astrocytes.

Iser IC, Lenz G, Wink MR.

Neurochem Int. 2019 Jan;122:139-143. doi: 10.1016/j.neuint.2018.11.016. Epub 2018 Nov 26.

PMID:
30496766
10.

Temporal autoregulation during human PU.1 locus SubTAD formation.

Schuetzmann D, Walter C, van Riel B, Kruse S, König T, Erdmann T, Tönges A, Bindels E, Weilemann A, Gebhard C, Wethmar K, Perrod C, Minderjahn J, Rehli M, Delwel R, Lenz G, Gröschel S, Dugas M, Rosenbauer F.

Blood. 2018 Dec 20;132(25):2643-2655. doi: 10.1182/blood-2018-02-834721. Epub 2018 Oct 12.

PMID:
30315124
11.

Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma.

Kessler T, Baumeier A, Brand C, Grau M, Angenendt L, Harrach S, Stalmann U, Schmidt LH, Gosheger G, Hardes J, Andreou D, Dreischalück J, Lenz G, Wardelmann E, Mesters RM, Schwöppe C, Berdel WE, Hartmann W, Schliemann C.

Transl Oncol. 2018 Dec;11(6):1271-1282. doi: 10.1016/j.tranon.2018.08.004. Epub 2018 Aug 17.

12.

FHIRChain: Applying Blockchain to Securely and Scalably Share Clinical Data.

Zhang P, White J, Schmidt DC, Lenz G, Rosenbloom ST.

Comput Struct Biotechnol J. 2018 Jul 29;16:267-278. doi: 10.1016/j.csbj.2018.07.004. eCollection 2018.

13.

A Suite of Transgenic Driver and Reporter Mouse Lines with Enhanced Brain-Cell-Type Targeting and Functionality.

Daigle TL, Madisen L, Hage TA, Valley MT, Knoblich U, Larsen RS, Takeno MM, Huang L, Gu H, Larsen R, Mills M, Bosma-Moody A, Siverts LA, Walker M, Graybuck LT, Yao Z, Fong O, Nguyen TN, Garren E, Lenz GH, Chavarha M, Pendergraft J, Harrington J, Hirokawa KE, Harris JA, Nicovich PR, McGraw MJ, Ollerenshaw DR, Smith KA, Baker CA, Ting JT, Sunkin SM, Lecoq J, Lin MZ, Boyden ES, Murphy GJ, da Costa NM, Waters J, Li L, Tasic B, Zeng H.

Cell. 2018 Jul 12;174(2):465-480.e22. doi: 10.1016/j.cell.2018.06.035.

PMID:
30007418
14.

90 Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single-center experience.

Spukti EU, Schmidt LH, Schulze A, Schliemann C, Görlich D, Wardelmann E, Hartmann W, Lenz G, Berdel WE, Kerkhoff A.

Eur J Haematol. 2018 Oct;101(4):514-521. doi: 10.1111/ejh.13138. Epub 2018 Sep 3.

PMID:
29993147
15.

Transcriptional characterization of immunological infiltrates and their relation with glioblastoma patients overall survival.

Pereira MB, Barros LRC, Bracco PA, Vigo A, Boroni M, Bonamino MH, Lenz G.

Oncoimmunology. 2018 Feb 12;7(6):e1431083. doi: 10.1080/2162402X.2018.1431083. eCollection 2018.

16.

Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer.

Mikesch JH, Schwammbach D, Hartmann W, Schmidt LH, Schliemann C, Angenendt L, Wiewrodt R, Marra A, Thoennissen NH, Wardelmann E, Köhler G, Lenz G, Müller-Tidow C, Berdel WE, Arteaga MF.

Eur Respir J. 2018 Jul 11;52(1). pii: 1701637. doi: 10.1183/13993003.01637-2017. Print 2018 Jul.

PMID:
29853494
17.

Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases.

Schliemann C, Kerkhoff A, Hesse P, Bröckling S, Hardes J, Streitbürger A, Andreou D, Gosheger G, Elges S, Wardelmann E, Hartmann W, Mesters R, Lenz G, Willich N, Kriz J, Eich H, Berdel WE, Kessler T.

PLoS One. 2018 May 22;13(5):e0197315. doi: 10.1371/journal.pone.0197315. eCollection 2018.

18.

Autophagy in glioma cells: An identity crisis with a clinical perspective.

Ulasov IV, Lenz G, Lesniak MS.

Cancer Lett. 2018 Aug 1;428:139-146. doi: 10.1016/j.canlet.2018.04.034. Epub 2018 Apr 27.

PMID:
29709703
19.

Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas.

Schmitz N, Lenz G, Stelljes M.

Blood. 2018 Jul 19;132(3):245-253. doi: 10.1182/blood-2018-01-791335. Epub 2018 Apr 26. Review.

PMID:
29699989
20.

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma.

Schleussner N, Merkel O, Costanza M, Liang HC, Hummel F, Romagnani C, Durek P, Anagnostopoulos I, Hummel M, Jöhrens K, Niedobitek A, Griffin PR, Piva R, Sczakiel HL, Woessmann W, Damm-Welk C, Hinze C, Stoiber D, Gillissen B, Turner SD, Kaergel E, von Hoff L, Grau M, Lenz G, Dörken B, Scheidereit C, Kenner L, Janz M, Mathas S.

Leukemia. 2018 Sep;32(9):1994-2007. doi: 10.1038/s41375-018-0045-9. Epub 2018 Mar 28.

21.

Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma.

Dunleavy K, Erdmann T, Lenz G.

Cancer Treat Rev. 2018 Apr;65:41-46. doi: 10.1016/j.ctrv.2018.01.002. Epub 2018 Feb 1. Review.

PMID:
29549872
22.

High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia.

Steckel NK, Groth C, Mikesch JH, Trenschel R, Ottinger H, Kordelas L, Mueller-Tidow C, Schliemann C, Reicherts C, Albring JC, Silling G, Schmidt E, Berdel WE, Lenz G, Ditschkowski M, Beelen DW, Stelljes M.

Br J Haematol. 2018 Mar;180(6):840-853. doi: 10.1111/bjh.15137. Epub 2018 Feb 21.

PMID:
29468631
23.

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development.

Gu JJ, Singh A, Xue K, Mavis C, Barth M, Yanamadala V, Lenz P, Grau M, Lenz G, Czuczman MS, Hernandez-Ilizaliturri FJ.

Oncotarget. 2017 Dec 19;9(3):4020-4033. doi: 10.18632/oncotarget.23425. eCollection 2018 Jan 9.

24.

The developing human connectome project: A minimal processing pipeline for neonatal cortical surface reconstruction.

Makropoulos A, Robinson EC, Schuh A, Wright R, Fitzgibbon S, Bozek J, Counsell SJ, Steinweg J, Vecchiato K, Passerat-Palmbach J, Lenz G, Mortari F, Tenev T, Duff EP, Bastiani M, Cordero-Grande L, Hughes E, Tusor N, Tournier JD, Hutter J, Price AN, Teixeira RPAG, Murgasova M, Victor S, Kelly C, Rutherford MA, Smith SM, Edwards AD, Hajnal JV, Jenkinson M, Rueckert D.

Neuroimage. 2018 Jun;173:88-112. doi: 10.1016/j.neuroimage.2018.01.054. Epub 2018 Jan 31.

25.

Analysis of NTPDase2 in the cell membrane using fluorescence recovery after photobleaching (FRAP).

Kipper FC, Tamajusuku ASK, Minussi DC, Vargas JE, Battastini AMO, Kaczmarek E, Robson SC, Lenz G, Wink MR.

Cytometry A. 2018 Feb;93(2):232-238. doi: 10.1002/cyto.a.23317. Epub 2018 Jan 24.

26.

Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.

Hershkovitz-Rokah O, Pulver D, Lenz G, Shpilberg O.

Br J Haematol. 2018 May;181(3):306-319. doi: 10.1111/bjh.15108. Epub 2018 Jan 23. Review.

PMID:
29359797
27.

Evolution of a designed protein assembly encapsulating its own RNA genome.

Butterfield GL, Lajoie MJ, Gustafson HH, Sellers DL, Nattermann U, Ellis D, Bale JB, Ke S, Lenz GH, Yehdego A, Ravichandran R, Pun SH, King NP, Baker D.

Nature. 2017 Dec 21;552(7685):415-420. doi: 10.1038/nature25157. Epub 2017 Dec 13.

28.

t-Darpp Activates IGF-1R Signaling to Regulate Glucose Metabolism in Trastuzumab-Resistant Breast Cancer Cells.

Lenz G, Hamilton A, Geng S, Hong T, Kalkum M, Momand J, Kane SE, Huss JM.

Clin Cancer Res. 2018 Mar 1;24(5):1216-1226. doi: 10.1158/1078-0432.CCR-17-0824. Epub 2017 Nov 27.

29.

CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.

Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwöppe C, Hartmann W.

Lung Cancer. 2017 Nov;113:121-127. doi: 10.1016/j.lungcan.2017.09.013. Epub 2017 Sep 22.

PMID:
29110838
30.

Prostate specific membrane antigen (PSMA) expression in non-small cell lung cancer.

Schmidt LH, Heitkötter B, Schulze AB, Schliemann C, Steinestel K, Trautmann M, Marra A, Hillejan L, Mohr M, Evers G, Wardelmann E, Rahbar K, Görlich D, Lenz G, Berdel WE, Hartmann W, Wiewrodt R, Huss S.

PLoS One. 2017 Oct 27;12(10):e0186280. doi: 10.1371/journal.pone.0186280. eCollection 2017.

31.

Individualisierte Therapie des metastasierten Lungenkarzinoms.

Evers G, Mohr M, Kerkhoff A, Lenz G, Wiewrodt R, Schmidt LH.

Dtsch Med Wochenschr. 2017 Oct;142(20):1531-1534. doi: 10.1055/s-0043-103471. Epub 2017 Oct 10. German.

PMID:
29017211
32.

Culture conditions defining glioblastoma cells behavior: what is the impact for novel discoveries?

Ledur PF, Onzi GR, Zong H, Lenz G.

Oncotarget. 2017 Aug 11;8(40):69185-69197. doi: 10.18632/oncotarget.20193. eCollection 2017 Sep 15. Review.

33.

Hyperthermia and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death.

de Andrade Mello P, Bian S, Savio LEB, Zhang H, Zhang J, Junger W, Wink MR, Lenz G, Buffon A, Wu Y, Robson SC.

Oncotarget. 2017 Jun 21;8(40):67254-67268. doi: 10.18632/oncotarget.18595. eCollection 2017 Sep 15.

34.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL.

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4.

PMID:
28976790
35.

Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.

Frick M, Bettstetter M, Bertz S, Schwarz-Furlan S, Hartmann A, Richter T, Lenze D, Hummel M, Dreyling M, Lenz G, Gaumann A.

Leuk Lymphoma. 2018 May;59(5):1260-1263. doi: 10.1080/10428194.2017.1370546. Epub 2017 Sep 3. No abstract available.

PMID:
28868954
36.

Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas.

Kipper FC, Silva AO, Marc AL, Confortin G, Junqueira AV, Neto EP, Lenz G.

Invest New Drugs. 2018 Apr;36(2):323-331. doi: 10.1007/s10637-017-0503-7. Epub 2017 Aug 29.

PMID:
28852916
37.

Correction: Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Aug 9;12(8):e0183201. doi: 10.1371/journal.pone.0183201. eCollection 2017.

38.

NEK1 kinase domain structure and its dynamic protein interactome after exposure to Cisplatin.

Melo-Hanchuk TD, Slepicka PF, Meirelles GV, Basei FL, Lovato DV, Granato DC, Pauletti BA, Domingues RR, Leme AFP, Pelegrini AL, Lenz G, Knapp S, Elkins JM, Kobarg J.

Sci Rep. 2017 Jul 14;7(1):5445. doi: 10.1038/s41598-017-05325-w.

39.

Deletion of eIF2β lysine stretches creates a dominant negative that affects the translation and proliferation in human cell line: A tool for arresting the cell growth.

Salton GD, Laurino CCFC, Mega NO, Delgado-Cañedo A, Setterblad N, Carmagnat M, Xavier RM, Cirne-Lima E, Lenz G, Henriques JAP, Laurino JP.

Cancer Biol Ther. 2017 Aug 3;18(8):560-570. doi: 10.1080/15384047.2017.1345383. Epub 2017 Jul 10.

40.

An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

Angenendt L, Reuter S, Kentrup D, Benk AS, Neumann F, Hüve J, Martens AC, Schwöppe C, Kessler T, Schmidt LH, Sauer T, Brand C, Mikesch JH, Lenz G, Mesters RM, Müller-Tidow C, Hartmann W, Wardelmann E, Neri D, Berdel WE, Roesli C, Schliemann C.

Leukemia. 2018 Feb;32(2):510-519. doi: 10.1038/leu.2017.208. Epub 2017 Jun 30.

PMID:
28663580
41.

Low Dose of Doxorubicin Potentiates the Effect of Temozolomide in Glioblastoma Cells.

Villodre ES, Kipper FC, Silva AO, Lenz G, Lopez PLDC.

Mol Neurobiol. 2018 May;55(5):4185-4194. doi: 10.1007/s12035-017-0611-6. Epub 2017 Jun 13.

PMID:
28612256
42.

Potential therapeutic impact of CD13 expression in non-small cell lung cancer.

Schmidt LH, Brand C, Stucke-Ring J, Schliemann C, Kessler T, Harrach S, Mohr M, Görlich D, Marra A, Hillejan L, Müller-Tidow C, Lenz G, Wardelmann E, Wiewrodt R, Berdel WE, Schwöppe C, Hartmann W.

PLoS One. 2017 Jun 12;12(6):e0177146. doi: 10.1371/journal.pone.0177146. eCollection 2017. Erratum in: PLoS One. 2017 Aug 9;12 (8):e0183201.

43.

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.

Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, Feller AC, Klapper W, Szczepanowski M, Hummel M, Stein H, Lenze D, Hansmann ML, Hartmann S, Möller P, Cogliatti S, Lenz G, Trümper L, Löffler M, Schmitz N, Pfreundschuh M, Rosenwald A, Ott G; German High-Grade Lymphoma Study Group.

J Clin Oncol. 2017 Aug 1;35(22):2515-2526. doi: 10.1200/JCO.2016.70.3660. Epub 2017 May 19.

PMID:
28525305
44.

Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma.

Matern S, Schmidt E, Hartmann D, Schliemann C, Groth C, Lenz G, Hartmann W, Klapper W, Berdel W, Stelljes M.

Ann Hematol. 2017 Jul;96(7):1201-1203. doi: 10.1007/s00277-017-3000-3. Epub 2017 Apr 27. No abstract available.

PMID:
28451803
45.

Deciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia.

Lenz G.

J Clin Oncol. 2017 May 1;35(13):1451-1452. doi: 10.1200/JCO.2016.72.0102. Epub 2017 Mar 14. No abstract available.

PMID:
28291389
46.

Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.

Erdmann T, Klener P, Lynch JT, Grau M, Vočková P, Molinsky J, Tuskova D, Hudson K, Polanska UM, Grondine M, Mayo M, Dai B, Pfeifer M, Erdmann K, Schwammbach D, Zapukhlyak M, Staiger AM, Ott G, Berdel WE, Davies BR, Cruzalegui F, Trneny M, Lenz P, Barry ST, Lenz G.

Blood. 2017 Jul 20;130(3):310-322. doi: 10.1182/blood-2016-12-758599. Epub 2017 Feb 15.

47.

Mature aggressive B-cell lymphoma across age groups - molecular advances and therapeutic implications.

Lange J, Lenz G, Burkhardt B.

Expert Rev Hematol. 2017 Feb;10(2):123-135. doi: 10.1080/17474086.2017.1271318. Epub 2016 Dec 26. Review.

PMID:
27936978
48.

The molecular pathogenesis of mantle cell lymphoma.

Vogt N, Dai B, Erdmann T, Berdel WE, Lenz G.

Leuk Lymphoma. 2017 Jul;58(7):1530-1537. doi: 10.1080/10428194.2016.1248965. Epub 2016 Nov 28. Review.

PMID:
27894215
49.

Ratiometric analysis of Acridine Orange staining in the study of acidic organelles and autophagy.

Thomé MP, Filippi-Chiela EC, Villodre ES, Migliavaca CB, Onzi GR, Felipe KB, Lenz G.

J Cell Sci. 2016 Dec 15;129(24):4622-4632. Epub 2016 Nov 14.

50.

B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.

Dai B, Grau M, Juilland M, Klener P, Höring E, Molinsky J, Schimmack G, Aukema SM, Hoster E, Vogt N, Staiger AM, Erdmann T, Xu W, Erdmann K, Dzyuba N, Madle H, Berdel WE, Trneny M, Dreyling M, Jöhrens K, Lenz P, Rosenwald A, Siebert R, Tzankov A, Klapper W, Anagnostopoulos I, Krappmann D, Ott G, Thome M, Lenz G.

Blood. 2017 Jan 19;129(3):333-346. doi: 10.1182/blood-2016-05-718775. Epub 2016 Nov 18.

Supplemental Content

Support Center